483 results on '"Miyachi, Hiroyuki"'
Search Results
2. 中分子創薬が直面する課題とその克服に向けて
3. Development of Integrated Database for Experiments and Simulations
4. Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands
5. Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids
6. Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives
7. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist
8. Anti-MRSA activity of isoplagiochin-type macrocyclic bis(bibenzyl)s is mediated through cell membrane damage
9. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis
10. Attempt to Create a Drug for Treatment of Fibrotic Diseases Based on the Non-genomic Action of Nuclear Receptors
11. Nongenomic Mechanism-Mediated Renal Fibrosis-Decreasing Activity of a Series of PPAR-γ Agonists
12. Arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists covalently bind to the PPARγ ligand binding domain with a unique binding mode
13. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility
14. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry–activity relationship
15. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist
16. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists
17. Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative
18. A nonclassical vitamin D receptor pathway suppresses renal fibrosis
19. Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton
20. Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ-selective partial agonists by disruption of molecular planarity/symmetry
21. Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method
22. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
23. Structure, solubility, and permeability relationships in a diverse middle molecule library
24. 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor
25. Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton
26. Co-existence of α-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development
27. Degradation-promoters of cellular inhibitor of apoptosis protein 1 based on bestatin and actinonin
28. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists
29. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist
30. Discovery of Carbono(di)thioates as Indoleamine 2,3-Dioxygenase 1 Inhibitors
31. Nongenomic Mechanism-Mediated Renal Fibrosis-Decreasing Activity of a Series of PPAR-γ Agonists
32. Design, synthesis, and evaluation of a novel series of α-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) α/δ dual agonists for the treatment of metabolic syndrome
33. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors
34. Ligands with a 3,3-diphenylpentane skeleton for nuclear vitamin D and androgen receptors: Dual activities and metabolic activation
35. Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPARα)-selective agonists
36. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice
37. Suppression of β-catenin signaling by liver X receptor ligands
38. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis
39. Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide
40. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands
41. Cyclic analogue of S-benzylisothiourea that suppresses kynurenine production without inhibiting indoleamine 2,3-dioxygenase activity
42. Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice
43. Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization
44. Fatty acid-binding protein ligands inhibit α-synuclein pathology in Parkinsonian mice
45. Design, Synthesis and Structure-activity Relationship Study of a Series of Bis(bibenzyl)-type Natural Products, Riccardin C Derivatives, as Candidate Anti-MRSA Agents
46. Structural development of 1,2,3,4-tetrahydroisoquinoline-type positive allosteric modulators of prostacyclin receptor (IPPAMs) to improve metabolic stability, and investigation of metabolic fate
47. Synthesis of both enantiomers of 1,2,3,4-tetrahydroisoquinoline derivative IPPAM-1 and enantio-dependency of its positive allosteric modulation of prostacyclin receptor
48. Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s
49. Discovery of peroxisome proliferator–activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line
50. Inhibitory Effects of a Novel PPAR-γAgonist MEKT1 onPomcExpression/ACTH Secretion in AtT20 Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.